Skip to main content

Drug Interactions between lamotrigine and PNV-OB with DHA

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

multivitamin, prenatal lamoTRIgine

Applies to: PNV-OB with DHA (multivitamin, prenatal) and lamotrigine

MONITOR: Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. The precise mechanism of interaction has not been established.

MONITOR: Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin. Some investigators suggest that folic acid may serve as a cofactor in the metabolism of phenytoin, thus clearance is increased in the presence of folic acid. In one study, administration of folic acid for 14 days reduced the serum levels of phenytoin in normal subjects without significantly altering the bound fraction. Urinary excretion of phenytoin and its metabolite, meta-hydroxydiphenylhydantoin, was increased. In another study, three of four folate-deficient male patients receiving phenytoin monotherapy for epilepsy demonstrated a 7.5% to 47.6% decrease in total phenytoin plasma concentration following the addition of folic acid 1 mg/day for 180 or 300 days. Ratios of urinary metabolites to parent drug increased in these patients, suggesting an increase in phenytoin oxidative metabolism. The interaction is further supported by case reports describing subtherapeutic phenytoin levels and/or breakthrough seizures following the addition of folate therapy, including one case involving folinic acid (leucovorin). Limited data are available for phenobarbital and primidone. In one study, the addition of folic acid 15 mg/day increased the frequency and severity of seizures in 13 of 26 folate-deficient epileptic patients receiving two or more anticonvulsant drugs, including phenytoin, phenobarbital, and primidone. Nine of them required discontinuation of folic acid therapy. No data are available for other hydantoins.

MANAGEMENT: Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.

References

  1. Furlanut M, Benetello P, Avogaro A, Dainese R (1978) "Effects of folic acid on phenytoin kinetics in healthy subjects." Clin Pharmacol Ther, 24, p. 294-7
  2. Carl GF, Smith ML (1992) "Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin." Epilepsia, 33, p. 372-5
  3. Berg MJ, Fincham RW, Ebert BE, Schottelius DD (1992) "Phenytoin pharmacokinetics: before and after folic acid administration." Epilepsia, 33, p. 712-20
  4. MacCosbe PE, Toomey K (1983) "Interaction of phenytoin and folic acid." Clin Pharm, 2, p. 362-9
  5. Robenberg IH (1972) "Drugs and folic acid absorption." Gastroenterology, 63, p. 353-7
  6. Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr (1975) "Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics." Am J Clin Nutr, 28, p. 51-8
  7. Katz M (1973) "Potential danger of self-medication with folic acid." N Engl J Med, 289, p. 1095
  8. Yuen GJ (1984) "Interaction of phenytoin and folic acid: an alternative explanation." Clin Pharm, 3, 116,119
  9. Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD (1983) "Phenytoin and folic acid: individualized drug-drug interaction." Ther Drug Monit, 5, p. 395-9
  10. Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD (1983) "Phenytoin and folic acid interaction: a preliminary report." Ther Drug Monit, 5, p. 389-94
  11. Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D (1995) "Folic acid improves phenytoin pharmacokinetics." J Am Diet Assoc, 95, p. 352-6
  12. Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ (1995) "Phenytoin-folic acid interaction." Ann Pharmacother, 29, p. 726-35
  13. "Product Information. Wellcovorin (leucovorin)." Glaxo Wellcome, Research Triangle Park, NC.
  14. Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M (1999) "Phenytoin-folic acid interaction: A lesson to be learned." Clin Neuropharmacol, 22, p. 268-72
  15. Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE (2004) "Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy." Br J Cancer, 90, p. 745
  16. Steinweg DL, Bentley ML (2005) "Seizures following reduction in phenytoin level after orally administered folic acid." Neurology, 64, p. 1982
  17. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  18. Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
  19. Cerner Multum, Inc. "Australian Product Information."
  20. (2008) "Product Information. Levoleucovorin (levoleucovorin)." Spectrum Chemical
  21. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  22. (2018) "Product Information. L-Methylfolate Calcium (l-methylfolate)." Virtus Pharmaceuticals LLC
View all 22 references

Switch to consumer interaction data

Drug and food interactions

Moderate

multivitamin, prenatal food

Applies to: PNV-OB with DHA (multivitamin, prenatal)

ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.

Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.

MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.

References

  1. "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
  2. (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics

Switch to consumer interaction data

Moderate

lamoTRIgine food

Applies to: lamotrigine

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
View all 4 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer